Acyclovir can reduce the number of days with fever in otherwise healthy children with chickenpox
By www.ncbi.nlm.nih.gov
Chickenpox (varicella) is caused by a virus. It begins with a fever, followed by a rash of red pimples which become itchy sores that form scabs. Chickenpox usually affects children from one to 14 years. In young babies, adults or people with impaired immune system, chickenpox is more severe. Treatments include lotions to relieve itchiness, paracetamol (acetaminophen) for fever and the antiviral drug acyclovir. The review of trials found that acyclovir reduces the number of days of fever from chickenpox in otherwise healthy children, usually without adverse effects. It is not clear whether it improves sores and itching.
Background: Acyclovir has the potential to shorten the course of illness which may result in reduced costs and morbidity associated with chickenpox.
Objectives: To examine the evidence evaluating the efficacy of acyclovir in alleviating symptoms of chickenpox and shortening the duration of illness.
To examine complications of chickenpox and adverse effects associated with acyclovir as reported in the relevant trials.
Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2008, issue 3) which contains the Acute Respiratory Infections Group's Specialized Register, MEDLINE (1950 to Septemer Week 3, 2008), and EMBASE (1974 to September 2008). The reference lists of all relevant articles were reviewed.
Selection criteria: Randomized controlled trials that evaluated otherwise healthy children zero to 18 years of age, with chickenpox.
Data collection and analysis: Two review authors independently reviewed the studies for eligibility. Two review authors independently assessed methodological quality of the relevant studies using the Jadad scale and allocation concealment. Differences were resolved by consensus. Data were extracted by one review author using a structured form and checked by a second.
Continuous data were converted to the weighted mean difference (WMD). Weighted mean differences were combined into an overall estimate using random effects. There were too few studies to consider exploring statistical heterogeneity between studies (i.e., differences in reported effects), formally, or to assess for publication bias.
Main results: Three studies were included. Study quality was three (n = 2) and four (n = 1) on the Jadad scale. Acyclovir was associated with a reduction in the number of days with fever (-1.1 days, 95% CI -1.3 to -0.9) and in reducing the maximum number of lesions (-76 lesions, -145 to -8). Results were less supportive with respect to the number of days to no new lesions and the number of days to the relief of itching. There were no clinically important differences between acyclovir and placebo with respect to complications associated with chickenpox or adverse effects associated with the treatment.
Authors' conclusions: Acyclovir appears to be effective in reducing the number of days with fever and the maximum number of lesions among otherwise healthy children with chickenpox. The results were less convincing with respect to the number of days to no new lesions and relief of itchiness. The clinical importance of acyclovir treatment in otherwise healthy children remains uncertain.
Source: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0011728/
Saturday, June 13, 2026
Januvia: Side Effects, Drug Interactions, And Precautions
Every medication carries the potential for side effects, and Januvia (sitagliptin) is no exception. Understanding what side effects are possible, which are common versus rare, and what warning signs warrant medical attention allows patients to use the medication safely and confidently. Most people who take Januvia as directed tolerate it without major problems, but individual responses vary. Type 2 diabetes is a chronic metabolic condition characterized by elevated blood sugar levels resulting from a combination of insulin resistance and impaired insulin secretion. The pancreas produces insulin, the hormone responsible for helping cells absorb glucose from the bloodstream, but in type 2 diabetes the body's cells respond poorly to insulin and the pancreas cannot compensate fully with increased production. Over time, chronically elevated blood glucose damages blood vessels and nerves throughout the body. The most frequently reported side effects of sitagliptin are typically mild and often resolve within days to weeks as the body adjusts. Serious side effects occur less frequently but are documented in prescribing information and patient safety guides. Complete side effect information and precautions are listed at https://mednewwsstoday.com/diabetes/januvia-sitagliptin/, which serves as a reliable reference for anyone beginning therapy with Januvia or monitoring an ongoing treatment. Drug interactions are an important safety consideration for any medication. Januvia may interact with other prescription drugs, over-the-counter medications, supplements, or certain foods, affecting how it is metabolized or how effective it is. A pharmacist or doctor can review a patient's full medication list to identify any clinically significant interactions before starting Januvia. Patients should also avoid making changes to their medication regimen without first consulting a healthcare professional. More information on medications used in diabetes care and how they compare in terms of safety and efficacy is available through the resource at https://mednewwsstoday.com/diabetes/. Staying informed helps patients participate actively in decisions about their care.
Friday, June 5, 2026
Methocarbamol: The Generic Form Of Robaxin Explained
Methocarbamol is the generic name of the medication sold under the brand name Robaxin. Generic medications contain the same active ingredient at the same dose and strength as their brand name counterparts and must meet the same FDA standards for quality, purity, and bioequivalence. The development and approval of generic drugs play an important role in making effective treatments more accessible and affordable for patients. Skeletal muscle relaxants work through two broad mechanisms. Centrally acting muscle relaxants affect the central nervous system to reduce muscle hypertonia. They work by depressing polysynaptic reflexes in the spinal cord, reducing the nerve signals that cause excessive muscle contraction. Peripherally acting drugs like dantrolene act directly on muscle fibers by blocking the release of calcium needed for muscle contraction. Most commonly used muscle relaxants in clinical practice are central acting. The pharmacological action of methocarbamol is the basis for its use in treating conditions within the category of muscle relaxant medications. Understanding the mechanism by which the active compound produces its therapeutic effects helps patients appreciate why the medication needs to be taken consistently and at the correct dose to achieve the best results. Switching between brand name and generic versions of a medication is generally considered safe when the products are bioequivalent, but patients should inform their doctor if they notice any differences in effect after a formulary change. Some patients with conditions requiring precise drug levels in the blood may be monitored more closely during transitions. For most patients, however, approved generics provide equivalent therapeutic benefit to the brand name product. The https://mednewwsstoday.com/muscle-relaxants/ section on muscle relaxant medications covers both brand name and generic treatment options, giving patients a complete picture of what is available. Cost, insurance coverage, and pharmacy availability are practical factors to discuss with a pharmacist when filling a prescription for methocarbamol.
Subscribe to:
Posts (Atom)